DIALIVE肝脏透析装置对比标准治疗在慢加急性肝衰竭患者中的随机对照临床试验
这项首次人体随机对照试验纳入32例酒精相关慢加急性肝衰竭患者,评估DIALIVE肝脏透析装置的安全性,主要终点为安全性,次要终点包括临床效果、装置性能及病理生理相关生物标志物。DIALIVE组内毒素血症严重程度和 albumin 功能显著改善,CLIF-C器官衰竭评分(p=0.018)和CLIF-C ACLF评分(p=0.042)在第10天显著降低,ACLF缓解时间显著更快(p=0.036),但28天死亡率或严重不良事件发生率组间无显著差异。作者认为DIALIVE似安全且对预后评分和病理生理相关生物标志物有积极影响,需更大规模充分把握度的研究进一步确认其安全性和有效性。
要点
- DIALIVE组第10天CLIF-C器官衰竭评分(p=0.018)和CLIF-C ACLF评分(p=0.042)较标准治疗组显著降低。
- DIALIVE组ACLF缓解时间显著更快(p=0.036),内毒素血症严重程度和albumin功能显著改善。
- 28天死亡率或严重不良事件发生率组间无显著差异,作者认为需更大规模研究进一步确认安全性和有效性。
核心结论
- 这些数据表明DIALIVE似安全,并对ACLF患者的预后评分和病理生理相关生物标志物有积极影响。
- 需要更大规模、有充分把握度的研究来进一步确认其安全性和有效性。
研究设计与样本
- 首次人体随机对照临床试验,纳入32例酒精相关慢加急性肝衰竭患者。
- DIALIVE治疗长达5天,第10天评估终点;安全性在所有32例患者中评估。
- 次要目标在预先设定的至少接受3次DIALIVE治疗的亚组(n=30)中评估。
- 临床试验注册号:NCT03065699。
主要发现
- 28天死亡率或严重不良事件发生率组间无显著差异。
- DIALIVE组内毒素血症严重程度显著降低,albumin功能显著改善。
- 第10天DIALIVE组CLIF-C器官衰竭评分显著降低(p=0.018),CLIF-C ACLF评分显著降低(p=0.042)。
- DIALIVE组ACLF缓解时间显著更快(p=0.036)。
- DIALIVE组全身炎症生物标志物IL-8(p=0.006)、细胞死亡标志物细胞角蛋白-18 M30(p=0.005)和M65(p=0.029)、内皮功能标志物不对称二甲基精氨酸(p=0.002)、Toll样受体4配体(p=0.030)和炎症小体配体(p=0.002)显著改善。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 这是一项小型研究,未降低死亡率。
- 需要进一步更大规模的临床试验来再次确认其安全性和评估有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is characterized by severe systemic inflammation, multi-organ failure and high mortality rates. Its treatment is an urgent unmet need. DIALIVE is a novel liver dialysis device that aims to exchange dysfunctional albumin and remove damage- and pathogen-associated molecular patterns. This first-in-man randomized-controlled trial was performed with the primary aim of assessing the safety of DIALIVE in patients with ACLF, with secondary aims of evaluating its clinical effects, device performance and effect on pathophysiologically relevant biomarkers. METHODS: Thirty-two patients with alcohol-related ACLF were included. Patients were treated with DIALIVE for up to 5 days and end points were assessed at Day 10. Safety was assessed in all patients (n = 32). The secondary aims were assessed in a pre-specified subgroup that had at least three treatment sessions with DIALIVE (n = 30). RESULTS: There were no significant differences in 28-day mortality or occurrence of serious adverse events between the groups. Significant reduction in the severity of endotoxemia and improvement in albumin function was observed in the DIALIVE group, which translated into a significant reduction in the CLIF-C (Chronic Liver Failure consortium) organ failure (p = 0.018) and CLIF-C ACLF scores (p = 0.042) at Day 10. Time to resolution of ACLF was significantly faster in DIALIVE group (p = 0.036). Biomarkers of systemic inflammation such as IL-8 (p = 0.006), cell death [cytokeratin-18: M30 (p = 0.005) and M65 (p = 0.029)], endothelial function [asymmetric dimethylarginine (p = 0.002)] and, ligands for Toll-like receptor 4 (p = 0.030) and inflammasome (p = 0.002) improved significantly in the DIALIVE group. CONCLUSIONS: These data indicate that DIALIVE appears to be safe and impacts positively on prognostic scores and pathophysiologically relevant biomarkers in patients with ACLF. Larger, adequately powered studies are warranted to further confirm its safety and efficacy. IMPACT AND IMPLICATIONS: This is the first-in-man clinical trial which tested DIALIVE, a novel liver dialysis device for the treatment of cirrhosis and acute-on-chronic liver failure, a condition associated with severe inflammation, organ failures and a high risk of death. The study met the primary endpoint, confirming the safety of the DIALIVE system. Additionally, DIALIVE reduced inflammation and improved clinical parameters. However, it did not reduce mortality in this small study and further larger clinical trials are required to re-confirm its safety and to evaluate efficacy. CLINICAL TRIAL NUMBER: NCT03065699.
引用
- Agarwal B, Cañizares RB, Saliba F, et al. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure. J Hepatol. 2023. PMID: 37268222. doi:10.1016/j.jhep.2023.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。